National Health Investors Valuation
Is NHI * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NHI * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NHI * (MX$960.8) is trading below our estimate of fair value (MX$1543.48)
Significantly Below Fair Value: NHI * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NHI *?
Other financial metrics that can be useful for relative valuation.
What is NHI *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$2.67b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 11.9x |
Enterprise Value/EBITDA | 15.3x |
PEG Ratio | 3.9x |
Price to Earnings Ratio vs Peers
How does NHI *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 20.3x | ||
TERRA 13 FIBRA Terrafina | 4x | -42.3% | Mex$29.3b |
DANHOS 13 Fibra Danhos | 10.1x | 3.7% | Mex$33.6b |
FIBRAMQ 12 FIBRA Macquarie México | 4.4x | -21.5% | Mex$25.5b |
FSITES 20 Fideicomiso Opsimex | 62.7x | n/a | Mex$88.1b |
NHI * National Health Investors | 19.7x | 5.0% | Mex$2.7b |
Price-To-Earnings vs Peers: NHI * is expensive based on its Price-To-Earnings Ratio (19.7x) compared to the peer average (10.1x).
Price to Earnings Ratio vs Industry
How does NHI *'s PE Ratio compare vs other companies in the Global Health Care REITs Industry?
Price-To-Earnings vs Industry: NHI * is good value based on its Price-To-Earnings Ratio (19.7x) compared to the Global Health Care REITs industry average (32.1x).
Price to Earnings Ratio vs Fair Ratio
What is NHI *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 19.7x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NHI *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.